Author: [AUTHOR] Published on 9/1/2020 12:00:00 AM
Shahram Ejtemaei Mehr, PharmD, PhD, Postdoc, Center for Pharmacometrics and Molecular Discovery, School of Pharmacy, Union University, Jackson, Tennessee
Dr. Ejtemaei Mehr pursued his PhD at Tehran University of Medical Science in Iran after earning his PharmD degree. He first encountered an article about pharmacokinetic/pharmacodynamic modeling during his PhD program. The paper was published in Clinical Pharmacology & Therapeutics—this was also the first time he learned about ASCPT. Throughout the years, he has found the topics discussed in the ASCPT journal family intriguing. Years later, he is honored and pleased to become a member of the Society.
In 2016, Dr. Ejtemaei Mehr moved to Nashville, TN, and enrolled in a fellowship program in clinical pharmacology at Vanderbilt University Medical Center, allowing him to gain more experience in the field. After the fellowship program was completed, he went on to become an expert in pharmacometrics working as a research fellow of pharmacometrics in the Center for Pharmacometrics and Molecular Discovery at Union University.
Pharmacokinetic/pharmacodynamic (PK/PD) and physiologically‐based pharmacokinetic (PBPK) modeling and simulation of data from clinical trials and animal models of disease are currently Dr. Ejtemaei Mehr’s main fields of interest. He believes that clinical pharmacology, especially pharmacometrics, is the most crucial discipline of drug development, even in clinical practice. He is fascinated by ASCPT’s approach in concentrating on a combination of these two disciplines and specifically point to the creation of the PMK community.